Lobbying client
ORPHAZYME US, INC.
Development of Heat-Shock Protein response for treatment of neurodegenerative rare disease
Filings
5
Filed by
1
Reported in-house
—
Reported by firms
$45,000
Filings
5 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
4th Quarter - Termination (No Activity) 4th Quarter 2021
|
THE KPM GROUP DC LLC | — reported |
|
3rd Quarter - Report (No Activity) 3rd Quarter 2021
|
THE KPM GROUP DC LLC | — reported |
|
2nd Quarter - Amendment (No Activity) 2nd Quarter 2021
|
THE KPM GROUP DC LLC | — reported |
|
1st Quarter - Report 1st Quarter 2021
|
THE KPM GROUP DC LLC | $45,000 reported |
|
Registration 4th Quarter 2020
|
THE KPM GROUP DC LLC | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| THE KPM GROUP DC LLC | 4 | $45,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 1 |
| Medical/Disease Research/Clinical Labs | MED | 1 |
| Pharmacy | PHA | 1 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.